Sandbox:Asra

Jump to navigation Jump to search

Asra Firdous,M.B.B.S.[1]


Ewing's sarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Ewing's sarcoma from other diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Biopsy

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sandbox:Asra On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sandbox:Asra

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sandbox:Asra

CDC on Sandbox:Asra

Sandbox:Asra in the news

Blogs on Sandbox:Asra

Directions to Hospitals Treating Ewing's sarcoma

Risk calculators and risk factors for Sandbox:Asra

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2];Associate Editor(s)-in-Chief: Suveenkrishna Pothuru, M.B,B.S. [3];Assistant Editor(s)-In-Chief: Michael Maddaleni, B.S., Asra Firdous, M.B.B.S.

Overview

Ewing's sarcoma is the second most common malignant bone neoplasm commonly affecting children and adolescents. It usually affects patients in the second decade of life with a peak incidence around 15 years of age. It comprises 3% of all malignancies in pediatric patients and about 10-15% of childhood bone cancers. The overall incidence of Ewing's sarcoma is approximately estimated at 2.9 cases per million population in the U.S. Ewing's sarcoma is more common in males than females. It is more prevalent in whites than Africans.

Epidemiology and Demographics

Incidence

Mortality/Morbidity

The overall 5-year survival rate for patients with Ewing's Sarcoma is approximately 70% in primary lesions and 30% in metastatic disease.

Race

  • Ewing's Sarcoma is more prevalent in Caucasians than Asians or Hispanics.
  • African Americans and Africans are less likely to develop Ewing's Sarcoma.
  • The incidence in the Caucasians is 1.5 cases per million population.
  • The incidence in the Asians is 0.8 cases per million population.
  • The incidence in Africans is 0.2 cases per million population.

Age

  • Ewing's Sarcoma commonly affects children and adolescents between 10 and 20 years of age.
  • The median age at diagnosis is 15 years
  • In patients younger than 5 years, diagnosed in about 0.6 cases per million population.
  • In patients aged 10-14 years, diagnosed in about more than 5 cases per million population.

Gender

  • Males are more commonly affected than females. The male to female ratio is around 3:2.

Reference

Anemia of Prematurity Symptoms

The majority of patients with Anemia of Prematurity are asymptomatic. In premature infants with severe disease, symptoms are usually vague or non-specific.

  • Common symptoms of Anemia of Prematurity include
    • Tachycardia
    • Tachypnea
    • Decreased activity or lethargy
    • Difficulty feeding
    • Pallor
  • Less common symptoms of Anemia of Prematurity include
    • Poor weight gain despite adequate calorie intake
    • Breathing difficulties
    • Metabolic acidosis due to increased lactic acid production from anaerobic metabolism in the cells
    • Heart murmurs


Pathophysiology of Anemia of Prematurity

The exact pathogenesis of anemia of prematurity is not fully understood. It is thought that anemia of prematurity is the result of a combination of decreased erythropoietin production, increased erythropoietin metabolism, deficient iron stores, decreased RBC lifespan, and blood loss during phlebotomy.

Physiological anemia in newborns

Normally, all the newborns experience a fall in the haemoglobin concentration during the first few weeks of life. Healthy, fullterm infants usually develop anemia around 10-12 weeks of life after birth. Hemoglobin concentration never falls below 10 g/dl in healthy infants. Physiological anemia is well tolerated by and does not require any therapy.[2]

  1. Ewing's sarcoma. National cancer institute.http://www.cancer.gov/types/bone/hp/ewing-treatment-pdq#section/_1
  2. Strauss RG (2010). "Anaemia of prematurity: pathophysiology and treatment". Blood Rev. 24 (6): 221–5. doi:10.1016/j.blre.2010.08.001. PMC 2981681. PMID 20817366.